Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition.

International journal of molecular sciences - 21 May 2022

D'Ambrosio Concetta, Erriquez Jessica, Capellero Sonia, Cignetto Simona, Alvaro Maria, Ciamporcero Eric, Di Renzo Maria Flavia, Perera Timothy, Valabrega Giorgio, Olivero Martina

Abstract excerpt

The MET oncogene encodes a tyrosine kinase (TK) receptor. Its activation protects cells from death but also stimulates DNA damage response by triggering excess replicative stress. Transcriptomic classification of cancer cell lines based on MET expression showed that response to the PARP inhibitor (PARPi) olaparib is poorer in MET overexpressing cell lines. Accordingly, a high MET expressing lung carcinoma cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Ataxia Telangiectasia Mutated Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Haploinsufficiency

Share to Lung Neoplasms

Share to Mutation

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 35628590
DOI: 10.3390/ijms23105770
PMCID: PMC9146142

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition.PMID 35628590Read ↗

ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung AdenocarcinomaSemantic proximity Read ↗

Clinical potential of ATM inhibitors.Semantic proximity Read ↗

PARP inhibitor synthetic lethality in ATM biallelic mutant cancer cell lines is associated with BRCA1/2 and RAD51 downregulationSemantic proximity Read ↗

Ataxia telangiectasia mutated (ATM) kinase as a predictive biomarker in clinical oncology: implications for a precision treatment approach.Semantic proximity Read ↗

ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor OlaparibSemantic proximity Read ↗

Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft ModelsSemantic proximity Read ↗

Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor TypesSemantic proximity Read ↗

PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1/2 and MTAP status in breast cancer cellsSemantic proximity Read ↗

A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors.Semantic proximity Read ↗

Deletion of 11q in Neuroblastomas Drives Sensitivity to PARP Inhibition.Semantic proximity Read ↗

ATM-depletion in breast cancer cells confers sensitivity to PARP inhibitionSemantic proximity Read ↗

ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and ApoptosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.